83,919 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC bought a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 83,919 shares of the company's stock, valued at approximately $232,000. Cubist Systematic Strategies LLC owned about 0.13% of Inozyme Pharma at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of INZY. JPMorgan Chase & Co. raised its holdings in Inozyme Pharma by 345.5% in the fourth quarter. JPMorgan Chase & Co. now owns 128,872 shares of the company's stock valued at $357,000 after acquiring an additional 99,944 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Inozyme Pharma by 155.7% in the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock valued at $1,167,000 after acquiring an additional 256,599 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Inozyme Pharma by 13.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 504,670 shares of the company's stock valued at $1,398,000 after acquiring an additional 58,518 shares during the period. abrdn plc acquired a new position in shares of Inozyme Pharma in the 4th quarter valued at $472,000. Finally, Barclays PLC increased its holdings in shares of Inozyme Pharma by 261.4% in the 3rd quarter. Barclays PLC now owns 76,730 shares of the company's stock valued at $401,000 after acquiring an additional 55,497 shares during the period. Institutional investors and hedge funds own 88.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on INZY. Raymond James cut their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a report on Wednesday, March 12th. Needham & Company LLC cut shares of Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research note on Friday, May 16th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $4.00 price objective on shares of Inozyme Pharma in a research report on Friday, May 16th. TD Cowen downgraded shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Wedbush cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $11.75.

Inozyme Pharma Stock Up 0.1%

Shares of Inozyme Pharma stock traded up $0.01 on Thursday, hitting $3.96. 1,667,022 shares of the company's stock traded hands, compared to its average volume of 809,756. The stock has a market cap of $255.34 million, a P/E ratio of -2.54 and a beta of 1.35. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm's 50-day moving average is $1.27 and its 200 day moving average is $1.88. Inozyme Pharma, Inc. has a 52-week low of $0.72 and a 52-week high of $6.24.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Equities analysts anticipate that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.